<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02584777</url>
  </required_header>
  <id_info>
    <org_study_id>381401</org_study_id>
    <nct_id>NCT02584777</nct_id>
  </id_info>
  <brief_title>A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Myelofibrosis</brief_title>
  <official_title>A Phase II, Prospective, Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Asian Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post- Essential Thrombocythemia Myelofibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxalta now part of Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CTI BioPharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of
      pacritinib in Asian subjects with myelofibrosis (MF), which includes primary MF (PMF),
      post-polycythemia vera MF (PPV-MF) or post-essential thrombocythemia MF (PET-MF).
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants achieving a ≥35% reduction in spleen volume</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Measured by MRI or CT scan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with ≥50% reduction in total symptom score (TSS)</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Measured by the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) TSS 2.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with baseline platelet count &lt;100,000/μL achieving ≥35% reduction in spleen volume</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Measured by MRI or CT scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with baseline platelet count &lt;100,000/μL achieving ≥50% reduction in total symptom score (TSS)</measure>
    <time_frame>Baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with baseline platelet count &lt;50,000/μL achieving ≥35% reduction in spleen volume</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Measured by MRI or CT scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with baseline platelet count &lt;50,000/μL achieving ≥50% reduction in total symptom score (TSS)</measure>
    <time_frame>Baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant adverse events (AEs)</measure>
    <time_frame>Throughout the study period of approximately 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant changes in laboratory results</measure>
    <time_frame>Throughout the study period of approximately 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant changes in vital signs</measure>
    <time_frame>Throughout the study period of approximately 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant changes in electrocardiograms (ECGs)</measure>
    <time_frame>Throughout the study period of approximately 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pacritinib pharmacokinetic (PK) parameter: maximum observed concentration (Cmax)</measure>
    <time_frame>Baseline; weeks 3, 12 &amp; 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pacritinib pharmacokinetic (PK) parameter: Time of maximum observed concentration (Tmax)</measure>
    <time_frame>Baseline; weeks 3, 12 &amp; 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pacritinib pharmacokinetic (PK) parameter: minimum observed concentration (Cmin)</measure>
    <time_frame>Baseline; weeks 3, 12 &amp; 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pacritinib pharmacokinetic (PK) parameter: area under the concentration curve (AUC)</measure>
    <time_frame>Baseline; weeks 3, 12 &amp; 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pacritinib pharmacokinetic (PK) parameter: apparent volume of distribution (V/F)</measure>
    <time_frame>Baseline; weeks 3, 12 &amp; 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic parameter: Maximum observed effect (Emax)</measure>
    <time_frame>Baseline; weeks 3, 12 &amp; 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic parameter: time of maximum observed effect (tEmax)</measure>
    <time_frame>Baseline; weeks 3, 12 &amp; 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic parameter: area under the effect curve (AUEC)</measure>
    <time_frame>Baseline; weeks 3, 12 &amp; 24</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Primary Myelofibrosis</condition>
  <arm_group>
    <arm_group_label>Pacritinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pacritinib</intervention_name>
    <description>QD (Once a day)</description>
    <arm_group_label>Pacritinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Intermediate-1, intermediate-2, or high-risk PMF, PPV-MF or PET-MF as based on The
             Dynamic International Prognostic Scoring System (DIPSS) criteria

          2. Palpable splenomegaly ≥5 cm below the LCM in midclavicular line by physical
             examination

          3. TSS ≥13 on the MPN-SAF TSS 2.0, not including the inactivity question, based on a
             single assessment during screening visit

          4. Age ≥18 years old at the time of screening (or minimum age of legal consent consistent
             with local regulations, if minimum is &gt;18 years of age)

          5. ECOG performance status 0 to 3

          6. Peripheral blast count &lt;10%

          7. Absolute neutrophil count &gt;500/μL

          8. Participants who are platelet or RBC transfusion dependent are eligible

          9. Adequate liver and renal function, defined by liver transaminases (AST/serum glutamic
             oxaloacetic transaminase [SOOT] and alanine aminotransferase [ALT]/serum glutamic
             pyruvic transaminase [SGPT]) ≤3 × upper limit of normal ([ULN], AST/ALT ≤5 × ULN if
             transaminase elevation is related to MF), direct bilirubin ≤4 × ULN, and creatinine
             ≤2.5 mg/dL

         10. At least 6 months from prior splenic irradiation

         11. At least 12 months from prior 32P therapy

         12. At least 1 week since prior treatment (most recent dose) with a potent CYP3A4
             inhibitor or inducer

         13. At least 4 weeks since any experimental treatment for PMF, PPV-MF, or PET-MF

         14. At least 2 weeks since any treatment for PMF, PPV-MF, or PET-MF

         15. If fertile, both males and females must agree to use effective birth control.

         16. Able to understand and willing to complete symptom assessments using a
             patient-reported outcomes instrument and comply with treatment and study procedures of
             the protocol

         17. Able to understand and willing to sign the informed consent form (ICF)

         18. Participant is willing and able to comply with the requirements of the protocol

        Exclusion Criteria:

          1. Any GI or metabolic condition that could interfere with absorption of oral medication

          2. Life expectancy &lt;6 months

          3. Prior treatment with a JAK2 inhibitor

          4. Completed ASCT, or are eligible for and willing to complete ASCT

          5. History of splenectomy or planning to undergo splenectomy

          6. Uncontrolled intercurrent illness, including but not limited to ongoing active
             infection, or psychiatric illness, or social situation that, in the judgment of the
             treating physician, would limit compliance with study requirements

          7. Other malignancy within the last 3 years, other than curatively treated basal cell or
             squamous cell skin cancer, carcinoma in situ of the cervix, organ confined, or treated
             non-metastatic prostate cancer with negative prostate specific antigen, in situ breast
             carcinoma after complete surgical resection, or superficial transitional cell bladder
             carcinoma

          8. Inflammatory or chronic functional bowel disorder, such as Crohn's disease,
             inflammatory bowel disease, chronic diarrhea, or constipation

          9. Clinically symptomatic and uncontrolled cardiovascular disease

         10. History of any of the following within 6 months prior to first dose of pacritinib:
             myocardial infarction, severe/unstable angina, or symptomatic congestive heart failure

         11. New York Heart Association Class II, III, or IV congestive heart failure

         12. Participants with NCI CTCAE (version 4.03) Grade 2 cardiac arrhythmias may be
             considered for inclusion, with the approval of the medical monitor, if the arrhythmias
             are stable, asymptomatic and unlikely to affect participant safety. Participants will
             be excluded if they have ongoing cardiac dysrhythmias of NCI CTCAE Grade ≥3, QTc
             prolongation &gt;450 ms, or other conditions that increase the risk for QT interval
             prolongation (eg, heart failure, hypokalemia [defined as serum potassium &lt;3.0 mEq/L
             that is persistent and refractory to correction], or family history of long QT
             interval syndrome)

         13. Erythropoietic agent within 28 days prior to first dose of pacritinib

         14. Thrombopoietic agent within 14 days prior to first dose of pacritinib

         15. Known seropositivity for human immunodeficiency virus or syphilis, or known active
             hepatitis A, B or C virus infection

         16. Participant has participated in another clinical study involving an IP or
             investigational device within 30 days prior to enrollment or is scheduled to
             participate in another clinical study involving an IP or investigational device during
             the course of this study

         17. Participant is a family member or employee of the investigator

         18. If female, participant is pregnant or breastfeeding at the time of enrollment. Even if
             breastfeeding can be discontinued, the participant should not be enrolled in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ellen Hooper</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2015</study_first_submitted>
  <study_first_submitted_qc>October 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2015</study_first_posted>
  <last_update_submitted>October 19, 2017</last_update_submitted>
  <last_update_submitted_qc>October 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Post-essential thrombocythemia myelofibrosis</keyword>
  <keyword>Post-Polycythemia Vera Myelofibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Polycythemia</mesh_term>
    <mesh_term>Polycythemia Vera</mesh_term>
    <mesh_term>Thrombocythemia, Essential</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

